Drugs.com Releases Q3 Sales for Top 100 U.S. Drugs: Singulair Drops But Nexium and Abilify Remain the Leading Brands

Drugs.com Releases Q3 Sales for Top 100 U.S. Drugs: Singulair Drops But Nexium
                    and Abilify Remain the Leading Brands

Drugs.com, the leading online clinical drug resource, today released third
quarter 2012 U.S. prescription sales data for the top 100 drugs

PR Newswire

NEW YORK, Nov. 21, 2012

NEW YORK, Nov. 21, 2012 /PRNewswire/ --As in the previous quarter,
proton-pump inhibitors, antipsychotics and statins remain in the top-selling
therapeutic categories. Merck's asthma and allergy preventive Singulair
predictably drops out of the top five drugs due to Q3 patent loss.

Top Five Drugs by Sales, Q3 2012

Drug Name Sales ($000) % Change (previous
Nexium    $1,420,907   2.93%
Abilify  $1,405,226   1.89%
Crestor   $1,245,527   10.74%
Cymbalta  $1,158,353   9.50%
Humira    $1,152,261   13.45%

AstraZeneca's Nexium, not forecast to lose patent protection until May 2014,
once again holds the top spot with over $1.42 billion in sales. Otsuka's
leading antipsychotic Abilify continues to run a close race with Nexium,
posting sales of $1.40 billion. The antidepressant and pain modifier Cymbalta
and the TNF blocker Humira both break their way into the top five and exceed
sales of $1.15 billion.

Top Five Sales Gains, Q3 2012

Drug Name Gain ($000) % Change (previous
Humira    $136,622    +13.45%
Crestor   $120,825    +10.74%
Enbrel    $118,579    +12.51%
Cymbalta  $100,533    +9.50%
Copaxone  $79,255     +9.93%

Humira not only moves into the top five drugs by sales, but also displaces
escitalopram to claim the number-one spot for revenue gains with over $136
million. Enbrel, with a doubling of sales gains, is the only other brand
besides Humira to reappear in the top five sales gain in Q3 compared to Q2
2012. Crestor, Cymbalta and Copaxone all move into the top five, approaching
or exceeding double-digit gains.

Top Five Sales Losses, Q3 2012

Drug Name    Loss ($000) % Change (previous
Singulair    -$800,968   -62.20%
atorvastatin -$613,501   -78.25%
Lipitor      -$392,788   -67.80%
Eloxatin     -$251,500   -55.33%
Actos        -$241,058   -41.96%

Merck's Singulair drops 20 spots in sales ranking and loses over $800 million
in sales due to first-time generic competition. Takeda's Actos, which has been
slowly losing sales over the last 12 months, went generic in August and
quickly drops 42 percent of revenue.

"Unprecedented pharmaceutical sales losses continue to make headlines in Q3
2012, highlighted by the Singulair patent expiry in August," said Philip
Thornton, CEO of Drugs.com. "But these changes can be thought of as a win-win
situation -- generic availability enables cost-savings for patients, while
loss of exclusivity encourages the pharmaceutical industry to further develop
new and life-saving therapeutics."

Pfizer's Lipitor continues to slide and drops 68 spots to close the quarter
$392 million in the negative. As expected, the total dollar revenue of
Lipitor's generic counterpart atorvastatin rapidly declines, dropping by over
$613 million due to the market entrance of multiple generic manufacturers and
inevitable price erosion.

Lidoderm, Maxalt and Actoplus Met are the next major brands expected to feel
the effect of patent loss before the year's end.

Detailed data on the top 100 drugs can be accessed at:

About Drugs.com

Drugs.com is the leading online drug information resource with over eight
million unique visitors per month (ComScore, October 2012). Providing free,
independent, peer-reviewed, and up-to-date information at both consumer and
professional levels, Drugs.com empowers patients and caregivers to take charge
of their health and be more informed than ever before. The site includes many
interactive tools and mobile apps to assist consumers, healthcare
professionals and researchers, such as personal medication records, a drug
interaction checker, pill identification wizard, symptom checker, pharma sales
statistics and more.

For more information, visit: http://www.drugs.com/

This press release was issued through eReleases® Press Release Distribution.
For more information, visit http://www.ereleases.com.

SOURCE Drugs.com

Website: http://www.drugs.com
Contact: Paul Wager, Drugs.com Press Officer, +1-718-395-2473, press@drugs.com
Press spacebar to pause and continue. Press esc to stop.